Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own1.90% Shs Outstand77.36M Perf Week1.32%
Market Cap177.93M Forward P/E- EPS next Y-0.70 Insider Trans3.13% Shs Float70.88M Perf Month-14.50%
Income-51.10M PEG- EPS next Q-0.22 Inst Own23.10% Short Float18.74% Perf Quarter-22.30%
Sales2.20M P/S80.88 EPS this Y-117.40% Inst Trans44.90% Short Ratio10.40 Perf Half Y-32.55%
Book/sh-0.23 P/B- EPS next Y6.70% ROA-47.90% Target Price6.96 Perf Year-25.81%
Cash/sh1.18 P/C1.94 EPS next 5Y- ROE341.60% 52W Range1.99 - 5.05 Perf YTD-0.43%
Dividend- P/FCF- EPS past 5Y-6.50% ROI-213.90% 52W High-54.46% Beta2.20
Dividend %- Quick Ratio11.30 Sales past 5Y-40.80% Gross Margin- 52W Low15.58% ATR0.14
Employees90 Current Ratio11.70 Sales Q/Q12.50% Oper. Margin- RSI (14)44.46 Volatility3.87% 6.55%
OptionableYes Debt/Eq- EPS Q/Q22.60% Profit Margin- Rel Volume0.28 Prev Close2.33
ShortableYes LT Debt/Eq- EarningsAug 05 AMC Payout- Avg Volume1.28M Price2.30
Recom1.90 SMA20-5.39% SMA50-7.13% SMA200-21.40% Volume351,505 Change-1.29%
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Aug-15-19 04:05PM  AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium PR Newswire
Aug-12-19 07:48AM  Edited Transcript of ACRX earnings conference call or presentation 5-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-05-19 09:24PM  AcelRx Pharmaceuticals Inc (ACRX) Q2 2019 Earnings Call Transcript Motley Fool
05:35PM  AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM  AcelRx Pharmaceuticals Reports Second Quarter 2019 Financial Results PR Newswire
Aug-02-19 10:12AM  AcelRx to announce second quarter 2019 results and provide an update on the company's business on Monday, August 5th, 2019 PR Newswire -5.10%
Jul-25-19 10:33AM  Analysts Estimate AcelRx Pharmaceuticals (ACRX) to Report a Decline in Earnings: What to Look Out for Zacks
07:29AM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
Jul-01-19 02:00PM  AcelRx added to the Russell 2000® and 3000® indexes PR Newswire
Jun-28-19 06:53PM  Hedge Funds Have Never Been More Bullish On AcelRx Pharmaceuticals Inc (ACRX) Insider Monkey +20.48%
Jun-13-19 05:05PM  Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks
Jun-06-19 08:26PM  Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents +7.36%
Jun-03-19 07:00AM  AcelRx announces the closing of a $25 million senior secured debt facility PR Newswire -5.41%
May-17-19 09:00AM  AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why Zacks
May-09-19 03:21PM  AcelRx Pharmaceuticals Inc (ACRX) Q1 2019 Earnings Call Transcript Motley Fool -9.40%
12:48PM  Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today Motley Fool
May-08-19 06:15PM  AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:09PM  AcelRx Pharmaceuticals: 1Q Earnings Snapshot Associated Press
02:30PM  AcelRx Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-07-19 04:48PM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
May-01-19 10:33AM  Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-29-19 11:29AM  3 Stocks Peter Lynch Would Love Motley Fool
Apr-25-19 04:05PM  AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019 PR Newswire
Apr-20-19 09:06AM  Penny Stocks to Buy Using Technical Analysis for April 2019 Investopedia
Apr-11-19 04:37PM  AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting PR Newswire
Apr-09-19 11:05AM  Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Apr-03-19 09:16AM  Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy Zacks
Mar-28-19 09:00AM  AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-11-19 04:01PM  AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference PR Newswire -6.12%
Mar-08-19 12:03PM  Why AcelRx Pharmaceuticals Stock Is Sinking Today Motley Fool -13.03%
10:00AM  Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX) Zacks
Mar-07-19 04:01PM  AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Mar-04-19 10:43AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Feb-22-19 09:25AM  AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019 PR Newswire
Feb-19-19 10:00AM  Biotech Leaders to Watch This Week ACCESSWIRE +9.31%
09:35AM  4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19) ACCESSWIRE
Feb-11-19 09:30AM  Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year? Zacks
Jan-31-19 07:00AM  AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium PR Newswire
Jan-09-19 07:20AM  Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services Discovering Underlying Factors of Influence GlobeNewswire
Jan-07-19 08:30AM  AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain PR Newswire
Dec-27-18 09:23AM  2 Biotech Penny Stocks to Buy Right Now Motley Fool +7.31%
Dec-23-18 09:25PM  Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX) Insider Monkey
Dec-21-18 08:51AM  Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options Zacks
Dec-18-18 07:00AM  AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI) PR Newswire -5.56%
Dec-01-18 08:30AM  3 Stocks to Hold for the Next 20 Years Motley Fool
Nov-29-18 04:35PM  AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11 PR Newswire
Nov-21-18 09:25AM  New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE
Nov-19-18 05:53PM  Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 04:05PM  AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting PR Newswire -5.06%
Nov-09-18 01:43PM  Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today Motley Fool -16.11%
09:10AM  AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
07:35AM  Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM  AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Nov-07-18 05:19PM  AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference PR Newswire -8.97%
Nov-06-18 07:44AM  Powerful new opioid 500 times stronger than morphine approved in U.S. in spite of outcry MarketWatch -8.67%
Nov-05-18 05:38PM  Health Care Digest: Health's push onto the ballot, an exec's cancer story and more American City Business Journals -11.04%
12:06PM  Why AcelRx Pharmaceuticals Stock Is Slipping Today Motley Fool
10:00AM  Monday's Top Healthcare Stocks To Watch Ahead Of Elections ACCESSWIRE
07:00AM  Todays Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics ACCESSWIRE
06:40AM  3 Big Stock Charts for Monday: Coca-Cola, Kinder Morgan and Adobe InvestorPlace
Nov-02-18 07:19PM  Noting Military Potential, FDA Approves Powerful Painkiller Dsuvia The Wall Street Journal +15.66%
06:20PM  AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:17PM  AcelRx Pharmaceuticals: 3Q Earnings Snapshot Associated Press
04:05PM  AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
04:04PM  Amid opioid concerns, FDA approves Peninsula company's powerful painkiller American City Business Journals
03:34PM  U.S. FDA approves AcelRx Pharma's opioid pain drug Reuters
01:56PM  AcelRx announces FDA approval of DSUVIA PR Newswire
01:47PM  AcelRx Pharma's opioid pain drug gets U.S. FDA nod Reuters
Nov-01-18 11:28AM  Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-26-18 08:55AM  Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock? Zacks
Oct-24-18 02:57PM  On eve of FDA decision, Peninsula company battles backlash to pain-killing opioids American City Business Journals
09:52AM  On eve of FDA decision, Peninsula company battles backlash to pain-killing opioids American City Business Journals
Oct-23-18 03:07PM  As powerful new opioid nears FDA approval, critics ask if U.S. is stoking its drug crisis MarketWatch +10.67%
Oct-19-18 03:15PM  AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting PR Newswire -12.53%
10:02AM  Controversy builds over potent new opioid medication as U.S. senator calls on FDA to reject the drug MarketWatch
Oct-17-18 08:15AM  Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +5.29%
Oct-16-18 04:33PM  10 Hottest Stocks From October 16, 2018 Benzinga -7.46%
06:33AM  3 Biotechs Awaiting FDA Approval Decisions Motley Fool
Oct-15-18 04:01PM  DSUVIA Efficacy and Safety Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Conference PR Newswire +7.79%
12:37PM  Stock Market News Daily Roundup October 15 Market Exclusive
12:11PM  Why AcelRx Pharmaceuticals Inc. Is Jumping Today Motley Fool
11:38AM  AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally Zacks
Oct-12-18 04:15PM  FDA Advisory Committee Recommends Approval Of DSUVIA For The Treatment Of Moderate-To-Severe Acute Pain PR Newswire
07:10AM  AcelRx Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review DSUVIA New Drug Application PR Newswire
Oct-11-18 08:00AM  Todays Research Reports on Stocks to Watch: Neovasc and AcelRx Pharmaceuticals ACCESSWIRE +10.71%
06:30AM  AcelRx Pharmaceuticals Inc. Is Soaring -- Should You Be Buying? Motley Fool
Oct-10-18 04:26PM  Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst +35.66%
01:23PM  AcelRx shares surge after FDA staff says opioid safe Reuters
12:32PM  AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia Benzinga
12:20PM  FDA staff says AcelRx opioid painkiller safe and effective Reuters
Oct-08-18 07:30AM  The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs Benzinga
Sep-25-18 04:05PM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences in October PR Newswire -9.78%
08:00AM  Todays Research Reports on Stocks to Watch: Amarin Corporation and AcelRx Pharmaceuticals ACCESSWIRE
Sep-24-18 06:12PM  Here's Why AcelRx Pharmaceuticals, Inc. Jumped 16.5% on Monday Motley Fool +16.46%
Sep-11-18 07:00AM  AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA PR Newswire
Sep-05-18 08:54AM  Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock? Zacks
Aug-23-18 04:05PM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September PR Newswire
Aug-22-18 03:50PM  Edited Transcript of ACRX earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
07:50AM  New Research: Key Drivers of Growth for OncoSec Medical, AcelRx Pharmaceuticals, Cameco, Prestige Brand, Berry Global Group, and A-Mark Precious Metals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-20-18 07:00AM  AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium PR Newswire
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.Chief Executive OfficerJun 05Buy2.315,00011,550262,884Jun 06 06:02 AM
EDWARDS MARK GDirectorMar 12Buy2.9919,00056,890200,000Mar 12 02:15 PM
ASADORIAN RAFFIChief Financial OfficerFeb 28Buy2.813,64710,248124,397Mar 04 04:28 PM
Dasu Badri NChief Engineering OfficerFeb 28Buy2.819,20625,869113,267Mar 04 04:26 PM
Angotti Vincent J.Chief Executive OfficerFeb 28Buy2.813,2349,088257,884Mar 04 04:25 PM
Hamel Lawrence GChief Development OfficerFeb 28Buy2.813,68210,34678,053Mar 04 04:24 PM
Palmer Pamela PChief Medical OfficerFeb 28Buy2.818402,360541,724Mar 04 04:23 PM
ASADORIAN RAFFIChief Financial OfficerDec 14Buy2.785,00013,88352,000Dec 17 12:04 PM
Angotti Vincent J.Chief Executive OfficerDec 14Buy2.783,61010,02454,650Dec 17 12:05 PM
Angotti Vincent J.Chief Executive OfficerDec 12Buy2.9910,00029,89051,040Dec 12 07:31 PM
Palmer Pamela PChief Medical OfficerNov 19Buy3.0716,00049,120472,134Nov 19 06:13 PM
EDWARDS MARK GDirectorNov 15Buy2.8220,70058,376181,000Nov 15 06:35 PM
ASADORIAN RAFFIChief Financial OfficerNov 13Buy3.135,00015,64647,000Nov 13 01:53 PM
Hamel Lawrence GChief Development OfficerOct 15Sale5.005,21626,08029,795Oct 16 04:30 PM
Dasu Badri NChief Engineering OfficerOct 15Sale5.0028,351141,75554,061Oct 16 04:29 PM
Hamel Lawrence GChief Development OfficerSep 24Sale4.506,95331,28935,011Sep 26 05:54 PM